Cohort of Patients With Systemic Sclerosis Within the Framework of the RESO Reference Centre

Condition(s) studied

Investigational drug(s) / intervention(s)

Blood samples: 62 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation

Biopsy: Skin biopsies only for volunteers among patients

Bronchoalveolar samples: 50 ml of bronchoalveolar samples if pulmonary flare requires this type of exploration only for volunteers among patients

Biopsy: Digestives biopsies if requires this type of exploration in the standard of care only for volunteers among patients

Study summary

Systemic sclerosis (SSc) is a rare form of connective tissue disease characterized by vascular involvement and the intensity of fibrosis. The lack of available treatment is largely due to the very fragmented understanding of the pathophysiology of SSc. However, one of the keys to conducting quality research on this disease remains the development of well-documented patient cohorts with reliable biological samples. The main objective of this cohort is to study the natural progression of SSc in a cohort of patients followed over 5 years.

Eligibility

Primary outcome measure(s)

• Change of the main clinical characteristics of scleroderma patients — At baseline (Day 0) and 60 months after baseline
  Worsening of the SSc according to the onset of a renal crisis (according to arterial hypertension \> 150/85 mm Hg ), a pulmonary arterial hypertension (identified with a right heart catheterization), or an interstitial lung disease (identified with a chest CT-scan).

Trial sites (1)

More University Hospital, Bordeaux trials in France

Other trials for the same condition